Cybin Inc. Shareholders Vote on Rebrand to Helus Pharma

Cybin Inc. conducted a virtual Annual General and Special Meeting of Shareholders to decide on several key corporate governance changes. The primary resolution involved officially changing the company's name from Cybin Inc. to Helus Pharma Inc. as it continues to develop psychedelic-based therapeutics for mental health.

During the session, shareholders considered resolutions to appoint Zeifmans LLP as the company auditor and set the board of directors' size at eight members. The company nominated eight individuals for these board positions, including CEO Trevor Halstead and co-founder Eric So.

Chief Financial Officer Greg Cavers moved the resolutions for the auditor appointment, board size, and the rebranding. While the meeting concluded after the voting period, the company did not announce final vote totals during the session, stating that the results would be published at a later date.